Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Cravens & Co Advisors LLC

Cravens & Co Advisors LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,305 shares of the biopharmaceutical company’s stock after buying an additional 71 shares during the period. Regeneron Pharmaceuticals accounts for approximately 1.1% of Cravens & Co Advisors LLC’s investment portfolio, making the stock its 16th largest holding. Cravens & Co Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $1,372,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in REGN. Rakuten Securities Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the period. Stephens Consulting LLC bought a new position in Regeneron Pharmaceuticals during the second quarter valued at about $26,000. Sachetta LLC boosted its stake in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares in the last quarter. Lynx Investment Advisory bought a new position in Regeneron Pharmaceuticals during the second quarter valued at about $33,000. Finally, Family Firm Inc. bought a new position in Regeneron Pharmaceuticals during the second quarter valued at about $33,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $753.03 on Wednesday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $735.95 and a fifty-two week high of $1,211.20. The stock’s 50-day moving average is $929.13 and its two-hundred day moving average is $1,024.43. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm has a market cap of $82.75 billion, a P/E ratio of 18.63, a price-to-earnings-growth ratio of 2.89 and a beta of 0.15.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Truist Financial decreased their target price on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Wells Fargo & Company decreased their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, October 22nd. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Finally, Royal Bank of Canada decreased their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $1,099.55.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.